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ABSTRACT
Background: Drug-eluting stents have been used in patients to 
achieve success with low clinical and angiographic restenosis 
since 2002. Since late thrombosis adverse events were associ-
ated with first generation everolimus- and paclitaxel-eluting 
stents, second-generation everolimus and zotarolimus-eluting 
stents were developed. Methods: The POLAR registry was 
a prospective, non-randomised, multicentre study, which 
included 988 patients and 1,362 lesions that were treated 
with the Promus® everolimus-eluting stent. To represent 
clinical practice, almost all patient and lesion subtypes were 
included in this registry. Clinical follow-ups were performed 
at one, six, 12, and 24 months after the procedure. Results: 
Most of the patients were male (69.8%), with a mean age 
of 64.9  ±  9.4 years, 35.2% were diabetics, and 55% had 
been treated for acute coronary syndrome. The mean vessel 
diameter of the patients was 2.95  ±  0.43  mm, and their 
lesions extended 20.5  ±  5.6  mm. A total of 1.14  ±  0.38 
stents were implanted per patient, with a procedural suc-
cess rate of 96.6%. Major adverse cardiac events occurred 
in 4.5% of patients, and stent thrombosis was observed in 
five patients (0.5%) after 12 months of clinical follow-up. 
Conclusions: The present registry suggests that everolimus-
eluting stents are safe and effective in daily clinical prac-
tice, with a low rate of major adverse cardiac events after 
12 months of follow-up.
DESCRIPTORS: Drug-eluting stents. Coronary restenosis. 
Coronary thrombosis.
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RESUMO
Resultados Clínicos de Um Ano do Registro POLAR 
(PrOmus eluting stent registry in Latin AmeRica)
Introdução: Desde 2002, os stents farmacológicos são utili zados 
em diversas populações de pacientes objetivando al cançar 
elevados índices de sucesso, com baixas taxas de reestenose 
angiográfica e clínica. Com os resultados adversos em relação à 
trombose tardia associados aos stents farmacológicos de primeira 
geração eluidores de sirolimus e paclitaxel, surgiram recente-
mente os stents farmacológicos de segunda geração eluidores 
de zotarolimus e everolimus. Métodos: O re gistro POLAR é 
um registro prospectivo, não randomizado, multicêntrico, que 
incluiu 988 pacientes totalizando 1.362 lesões tratadas com 
o stent Promus®. Objetivando representar a prática clínica, 
praticamente todos os subtipos de pacientes e lesões foram 
incluídos neste registro. O seguimento clínico foi planejado para 
ser realizado 1 mês, 6 meses, 12 meses e 24 meses após o 
procedimento. Resultados: A maioria dos pacientes era do sexo 
masculino (69,8%), com média de idade de 64,9 ± 9,4 anos, 
35,2% eram diabéticos e 55% tinham sido tratados na vigên-
cia de síndrome coronária aguda. O diâmetro do vaso foi de 
2,95 ± 0,43 mm e a extensão da lesão, de 20,5 ± 5,6 mm. Foi 
implantado 1,14 ± 0,38 stent/paciente e o sucesso do procedi-
mento foi alcançado em 96,6% dos casos. Eventos cardíacos 
adversos maiores ocorreram em 4,1% dos pacientes, e trombose 
de stent esteve presente em 5 pacientes (0,5%) após o segui-
mento clínico de 12 meses. Conclusões: O presente registro 
sugere que os stents farmacológicos eluidores de everolimus 
são seguros e eficazes em pacientes da prática clínica diária, 
com baixas taxas de eventos cardíacos adversos maiores ao 
término do primeiro ano de seguimento.
DESCRITORES: Stents farmacológicos. Reestenose coronária. 
Trombose coronária.
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D rug-eluting stents have been a therapeutic ap-proach for coronary artery disease throughout the last decade, when the European regulatory 
agency approved the first two drug-eluting stents, the 
sirolimus (Cypher®, Cordis Corporation - Warren, United 
States) and paclitaxel-eluting (Taxus®, Boston Scientific 
– Natick, United States) stents. These stents were ap-
proved after study results that compared these devices 
with conventional stents.1,2
Despite initial encouraging results suggesting that 
first-generation drug-eluting stent restenosis incidence 
was reduced compared with that of conventional 
stents, there has been great concern after evidence 
showed increased rates of late and very late throm-
bosis with these new devices.3 Since then, developing 
new drug-eluting stents with similar efficacy to first-
generation stents and increased safety has become a 
priority. Second-generation stents were developed with 
reduced polymeric load and/or more biocompatible 
polymers. Among these new stents, the everolimus-
eluting stents have demonstrated promising initial 
results in controlled.4
The Promus® stent (Boston Scientific – Santa Clara, 
CA, USA) releases the antiproliferative drug everolimus 
from a stable, non-adhesive, thin biocompatible poly-
mer layer, which covers the thin strut cobalt-chrome 
platform.
The aim of the POLAR registry was to clinically 
eva luate the Promus® stent in patients in clinical prac-
tice and, therefore, not considered in initial controlled 
studies.
METHOD
Casuistry and clinical study design
The POLAR registry was a prospective, non-ran-
domised, multicentre study conducted after Promus® 
stent commercialisation to evaluate patient safety and 
clinical effectiveness of the Promus® stent in patients 
in current clinical practice.
From November of 2008 to July of 2010, 1,121 
patients with coronary lesions were treated with the 
Promus® stent in 40 Latin American centres. Of these 
patients, 133 were excluded for having received a 
nonstudy stent in addition to the Promus® stent.
Since the objective was to represent daily clini-
cal practice, the inclusion criteria were not strict 
and included >  18-year-old patients who underwent 
routine or emergency angioplasty. Patients with a life 
expectancy < 24 months were excluded from the study 
because it would not be possible to perform follow-up 
studies. Additionally, those with unfavourable coronary 
anatomy for percutaneous treatment and those who 
had to maintain dual antiplatelet therapy during the 
12 months were also excluded.
The Ethics Committees of all participant centres 
approved the registry protocol, and all of the patients 
signed an informed consent.
Coronary intervention procedure and 
antiaggregation protocol
The antiplatelet protocol consisted of using 
acetylsalicylic acid at a 300  mg loading dose and 
a 100  mg/day maintenance dose, and clopidogrel at 
a 300–600  mg/day loading dose and a 75  mg/day 
maintenance dose before stent implantation. After 
the procedure, acetylsalicylic acid treatment was 
recommended indefinitely, and clopidogrel treatment 
was recommended for a 12-month-period, following 
current clinical practice.
Pre-dilatation the number of stents implanted 
were left to the operator’s discretion. Post-dilatation 
was recommended when there was ≥  30% residual 
stenosis.
Objectives and definitions
The primary objective of this registry was to evaluate 
major adverse cardiac event (MACE) incidence, which 
is defined as the combined occurrence of cardiac 
death, non-fatal myocardial infarction, or target-lesion 
revascularisation after 12 months of clinical follow-
up. The secondary objectives were: rate of MACE six 
months post-procedure; technical success, defined as 
implantation associated with residual stenosis ≤  30% 
of Promus® stent in the target lesion; procedural suc-
cess, defined as technical success with no occurrence 
of MACE during hospitalization; and all deaths during 
hospitalization and after one month, six months, 12 
months, and 24 months.
The following definitions were applied to the 
aforementioned cardiac events. Cardiac death was any 
death that could not be attributed to a non-cardiac 
cause. Myocardial infarction occurred when at least 
one of the following criteria was present: increased 
creatine phosphokinase (CPK) levels of more than two 
times the normal upper limit with an altered creatine 
phosphokinase-MB fraction (CPK-MB); increased CPK 
levels greater than five times the normal upper limit 
for surgical myocardial revascularisation cases; > 1 ng/
mL increase of Troponin T or >  0.5  ng/mL AccuTnI; 
or electrocardiography results demonstrating new 
pathological Q-waves longer than ≥ 0.04 seconds in at 
least two derivations with borderline altered CPK-MB. 
Target vessel revascularisation was defined as a new 
percutaneous intervention procedure or myocardial 
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TABLE 1 
Demographic Data, Clinical Presentation, 
and Risk Factors
Clinical Features n = 988
Age, years 64.9 ± 9.4
Minimum-maximum 34-95
Male gender, % 69.8
Risk factor, %
Hypertension 80.7
Diabetes mellitus 35.2
 Using insulin 8.6
Dyslipidaemia 70.1
Current/past smoking 55.2
Prior PCI, % 31.4
Prior AMI, % 28
Clinical presentation, % 
Stable angina 45
Unstable angina 41.9
AMI without ST segment  
elevation
7.3
AMI with ST segment  
elevation
5.8
Moderate/severe 
ventricular dysfunction, % 
12.5
Prior medications, %
Beta-blocker 63.1
Angiotensin-converting enzyme  
inhibitor
34.8
Angiotensin II inhibitor 23.2
Statin 69.4
Adjunctive antiplatelet  
Therapy, %
Acetylsalicylic acid 97.8
Clopidogrel 98.8
Ticlopidine 1.1
AMI = acute myocardial infarction; PCI = percutaneous 
coronary intervention; N = number of patients.
revascularisation surgery in the same epicardial ves-
sel treated in the index procedure. Stent thrombosis 
definitions were based on those from the Academic 
Research Consortium (ARC),5 and were divided into 
definite stent thrombosis (angiographic or pathological 
confirmation), probable stent thrombosis (any death that 
could not be explained within 30 days or target vessel 
myocardial infarction without angiographic thrombosis 
confirmation) and possible stent thrombosis (any death 
that could not be explained within 30 days).
Clinical follow-up was performed via phone in-
terview or physician appointment at one month, six 
months, 12 months, and 24 months after Promus® stent 
implantation.
Data collection and management
The Cardiovascular Research Centre (São Paulo, SP, 
Brazil) was in charge of elaborating and implement-
ing the registry, performing the study, and monitoring 
the data.
Categorical variables were expressed as absolute 
frequencies and percentages. Continuous variables were 
expressed as mean ± standard deviation.
RESULTS
Table 1 demonstrates the base clinical and demo-
graphic features of the 988 treated patients. Most of 
the patients were men (69.8%) whose mean age was 
64.9 ± 9.4 years, and 35.2% were diabetic. Over half 
of the treated group had acute coronary syndrome 
(55%), most of the patients were using acetylsalicylic 
acid (97.8%), and one patient was using thienopyri-
dines (100%).
The left anterior descending artery was the most 
frequently treated vessel, and 55% of the lesions were 
B2/C type lesions (Table 2). The mean vessel diameter 
was 2.95  ±  0.43  mm, and the mean lesion length 
was 20.5  ±  5.6  mm. The patients received a mean of 
1.14 ± 0.38 stents, and the procedures were successful 
in 96.6% of cases. 
Data regarding 12-month clinical follow-up after 
the index procedure was obtained from 90.5% of 
the patients via outpatient or telephone appointment 
(Table 3). Cardiac death occurred in 0.7% of the 
patients, non-fatal myocardial infarction occurred in 
1.5%, and target lesion revascularisation occurred in 
1.9%, totalling a MACE rate of 4.1%. Five cases of 
stent thrombosis (0.5%) were verified. These cases 
occurred within the first six months after the proce-
dure. No additional cases were detected through 12 
months of follow-up.
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DISCUSSION
Data reported in this article were derived from the 
results obtained with the Promus® everolimus-eluting 
stent, and confirm previously published results for 
these stents.4–7
The SPIRIT Clinical Trial Program presented vari-
ous clinical trials that sought to test the clinical and 
angiographic effectiveness of the aforementioned stents. 
SPIRIT I5, included 26 randomised patients who had 
received everolimus-eluting stents. However, this initial 
publication already demonstrated that these stents had 
superior performance compared with first-generation stents.
In the SPIRIT II trial,6 300 patients were randomised 
3:1 to test the effectiveness of the everolimus-stent 
compared with the Taxus® paclitaxel-eluting stent. In 
this non-inferiority trial that featured late loss as a 
primary endpoint, the everolimus-eluting stent was 
superior to the paclitaxel-eluting stent (late lumen loss 
of 0.11  ±  0.27  mm vs. 0.36  ±  0.39  mm at 6 months; 
P  <  0.0001).
In the SPIRIT IV trial,7 3,687 patients with stable 
or unstable angina were randomised 2:1 for treatment 
with the everolimus-eluting stent (n  =  2,458) or the 
paclitaxel-eluting stent (n  =  1,229). After 12 months 
of follow-up, researchers observed superiority of the 
everolimus-eluting stent regarding target vessel failure 
(3.9% vs. 6.6%, P = 0.0008) and target lesion revascu-
larisation (2.5% vs. 4.6%, P  (non-inferiority) < 0.0001 
and P  (superiority)  =  0.09). Probable and definite 
thrombosis rates were also significantly lower with 
these stents (0.29% vs. 1.06%, P  =  0.003).
TABLE 2 
Angiographic and Procedure Features
 
N = 988 
(1,254 vessels, 
1,362 lesions)
Treated vessel, %
LAD 48.1
LCx 22.1
RCA 26.7
LMCA 2.2
Saphenous graft 0.9
Lesion classification  
(ACC/AHA), %
A 9.8
B1 35.1
B2 32.2
C 22.8
Thrombus, % 6.1
Calcification, % 28.1
Restenotic lesions, % 7.1
Chronic total occlusion, % 7
Vessel diameter, mm 2.95 ± 0.43
Lesion length, mm 20.5 ± 5.6
Stenosis diameter, % 84.3 ± 15
Access route, %
Femoral 68.9
Radial 29.5
Brachial 1.4
Pre-dilatation, % 58.1
Post-dilatation, % 25.1
Average stent number per  
patient
1.14 ± 0.38
Dissection after stent  
implantation, %
0.9
TIMI 3 flow after  
procedure, %
99.2
Procedure success, % 96.6
ACC/AHA = American College of Cardiology/American Heart 
Association; LAD = left anterior; LCx = left circumflex artery;  
RCA = right coronary artery; LMCA= left main coronary artery.
TABLE 3 
Adverse Events in 12 Months
Adverse Events n = 988
MACE, n (%) 41 (4.1)
Cardiac death, n (%) 7 (0.7)
Non-cardiac death, n (%) 6 (0.6)
Non-fatal myocardial  
infarction, n (%)
15 (1.5)
Target lesion revascularisation, n (%) 19 (1.9)
Target vessel revascularisation, n (%) 4 (0.4)
Stent thrombosis, n (%) 5 (0.5)
MACE = major adverse cardiac events (cardiac death, non-fatal 
acute myocardial infarction, or target vessel revascularisation; 
n = number of patients.
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In addition to the SPIRIT program, everolimus-eluting 
stents were also tested in the COMPARE,8 BASKET-
PROVE,9 ISAR-TEST 410, and SORT OUT IV11 studies. 
All of these studies demonstrated positive results for 
the new everolimus-eluting stents. 
A recent meta-analysis12 evaluated everolimus-
eluting stent safety in relation to thrombosis. In 
total, 17,101 patients were included, with an aver-
age follow-up period of 21.7 months. These devices 
demonstrated significant reductions in stent thrombosis 
(risk rate [RR] = 0.55, 95% confidence interval [95% 
CI] 0.38-0.78, P = 0.001) target vessel revascularisa-
tion (RR  =  0.78, 95% CI 0.64-0.92, P  =  0.004) and 
myocardial infarction (RR  =  0.78, 95%  CI 0.64-0.96, 
P  =  0.02) compared with the sirolimus-, paclitaxel- 
and zotarolimus-eluting stents.
The results of the present study are in aggreement 
with those from previous studies. With a large patient 
population and a 12-month follow-up period for more 
than 90% of the patients, it was possible to verify 
reduced event incidence for 12 months (4.1%), with 
a low rate of target vessel (0.4%) and target lesion 
revascularisation (1.9%). Moreover, this patient popu-
lation was representative of real-world interventional 
cardio logy, since the mean patient age was 64.9 ± 9.4 
years, 55% of the patients had acute coronary syndrome 
and 35.2% were diabetic.
The results shown here have relevant similarities 
to those from previously published registries. The first 
generation stent registries e-Cypher13 (n = 15,157), e-
SELECT14 (n = 15,147), and WISDOM15 (n = 778) had 
similar MACE (5.8%, 4.8%, and 5.2%, respectively) and 
stent thrombosis (0.88%, 1.3%, and 0.6%, respectively) 
results after 12 months of follow-up. The results from 
the second-generation stent studies RESOLUTE16 and 
BEACON17 were similar (4.1% and 6.5%, respectively, 
for MACE; and 1.2% and 0%, respectively, for stent 
thrombosis) after 12 months of follow-up.
Study limitations
This study’s main limitation is that it was not ran-
domised. Furthermore, because patient data for some 
treatment centres during the inclusion period was not 
available, a possible selection bias could not be ex-
cluded. Finally, strict adhesion to dual anticoagulant 
therapies could not be assured during patient follow-up. 
CONCLUSIONS
The present study evaluated the safety and effec-
tiveness of the Promus® everolimus-eluting stent in a 
minimally selected patient population. After a 12-month 
follow-up period, these devices were proven to be ef-
fective and safe with low rates of major adverse cardiac 
events and stent thrombosis.
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